News

Find News

Filter articles

Applied Filters

Showing 1 to 10 of 995 results

Groups urge Fed Circ to rehear Biogen patent case

US18-01-2022Alex Baldwin

Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

Bristol Meyers can’t convince circuit to overturn $1.2bn ruling

US18-01-2022Alex Baldwin

The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.

Hikma ‘skinny’ label does not infringe Amarin patents

US06-01-2022Muireann Bolger

Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

Apotex asks Supreme Court to overturn Teva ‘Bendeka’ ruling

US21-12-2021Alex Baldwin

Apotex has asked the US Supreme Court to reconsider a US Court of Appeals for the Federal Circuit ruling upholding four of Teva Pharmaceutical’s cancer drug patents.

BioDelivery Sciences ‘pleased’ with mixed ruling over Opioid drug claims

US21-12-2021Alex Baldwin

A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.

Gilead, BMS, Janssen facing HIV generic antitrust suit

US16-12-2021Muireann Bolger

Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.

Intubated patients sedative patent the focus of ACS Dobfar suit

US16-12-2021Alex Baldwin

Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.

Generics win anti-pay-for-delay bill challenge

US14-12-2021Alex Baldwin

The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

US13-12-2021Alex Baldwin

Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.

GSK responds to Teva’s ‘skinny’ label rehearing petition

US09-12-2021Alex Baldwin

Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.

Showing 1 to 10 of 995 results

LSIPR